Summit Therapeutics Inc (NASDAQ: SMMT) kicked off on Friday, up 3.15% from the previous trading day, before settling in for the closing price of $18.42. Over the past 52 weeks, SMMT has traded in a range of $1.89-$33.89.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -28.65% over the past five years. While this was happening, its average annual earnings per share was recorded 69.54%. With a float of $103.50 million, this company’s outstanding shares have now reached $701.66 million.
Let’s look at the performance matrix of the company that is accounted for 105 employees. In terms of profitability, gross margin is 385.96%, operating margin of 77226.38%, and the pretax margin is 83760.85%.
Summit Therapeutics Inc (SMMT) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Summit Therapeutics Inc is 85.96%, while institutional ownership is 11.49%. The most recent insider transaction that took place on Mar 27 ’24, was worth 201,874. In this transaction Chief Executive Officer of this company bought 54,321 shares at a rate of $3.72, taking the stock ownership to the 24,923,800 shares. Before that another transaction happened on Mar 26 ’24, when Company’s Chief Executive Officer bought 30,000 for $3.75, making the entire transaction worth $112,500. This insider now owns 30,000 shares in total.
Summit Therapeutics Inc (SMMT) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 69.54% per share during the next fiscal year.
Summit Therapeutics Inc (NASDAQ: SMMT) Trading Performance Indicators
Take a look at Summit Therapeutics Inc’s (SMMT) current performance indicators. Last quarter, stock had a quick ratio of 8.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.28, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.38 in one year’s time.
Technical Analysis of Summit Therapeutics Inc (SMMT)
Summit Therapeutics Inc (NASDAQ: SMMT) saw its 5-day average volume 1.61 million, a negative change from its year-to-date volume of 3.54 million. As of the previous 9 days, the stock’s Stochastic %D was 14.40%. Additionally, its Average True Range was 1.50.
During the past 100 days, Summit Therapeutics Inc’s (SMMT) raw stochastic average was set at 44.83%, which indicates a significant increase from 21.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.46% in the past 14 days, which was lower than the 117.86% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.89, while its 200-day Moving Average is $10.82. Nevertheless, the first resistance level for the watch stands at $19.46 in the near term. At $19.92, the stock is likely to face the second major resistance level. The third major resistance level sits at $20.40. If the price goes on to break the first support level at $18.52, it is likely to go to the next support level at $18.04. The third support level lies at $17.58 if the price breaches the second support level.
Summit Therapeutics Inc (NASDAQ: SMMT) Key Stats
The company with the Market Capitalisation of 14.00 billion has total of 737,448K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -614,930 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -56,250 K.
